Phillips, G L <br/><br/>
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.  [electronic resource] 

 -  Bone marrow transplantation  Apr 2004 
 - 781-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1704424  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Amifostine--administration & dosage<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Combined Modality Therapy<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Hodgkin Disease--therapy<br/>Humans<br/>Lymphoma, Non-Hodgkin--therapy<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Radiation-Protective Agents--administration & dosage<br/>Transplantation Conditioning--methods<br/>Transplantation, Autologous